研究单位：[1]Shenzhen NewDEL Biotech, Co., Ltd[2]Sun Yat-sen University[3]Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.[4]the First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China[5]Gansu Provincial Cancer Hospital,Lanzhou,Gansu,China[6]the first hospital of Lanzhou University,Lanzhou,Gansu,China[7]Sun Yat-sen University cancer center,Guangzhou,Guangdong,China[8]The Sixth Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,China[9]Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center,Shenzhen,Guangdong,China[10]Zhanjiang Central Hospital, Guangdong Medical University,Zhanjiang,Guangdong,China[11]Guangxi Medical University Cancer Hospital,Nanning,Guangxi,China[12]the Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China[13]Tongji Hospital Tongji Medical College of HUST,Wu'an,Hubei,China[14]Hunan Cancer Hospital,Changsha,Hunan,China[15]Jiangxi Cancer Hospital,Nanchang,Jiangxi,China[16]The First Hospital of China Medical University,Shenyang,Liaoning,China[17]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China[18]Shandong Cancer Hospital & Institute,Jinan,Shandong,China[19]Linyi Cancer Hospital,Linyi,Shandong,China[20]Sichuan Cancer Hospital,Chengdu,Sichuan,China[21]The Second People's Hospital of Neijiang,Neijiang,Sichuan,China[22]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China[23]Yunnan Cancer Hospital,Kunming,Yunnan,China[24]Sir Run Run Shaw Hospital,Hangzhou,Zhejiang,China
研究目的：
This study is done to test the safety and preliminary efficacy of drug ND-003 tablets in patients with solid tumors. ND-003 is a highly potent and selective small molecular inhibitor of NTRK (neurotrophic receptor tyrosine kinase) and RET (rearranged during transfection). The study also investigates how the drug is absorbed and processed in the human body.
